Etira’s ERX‑41 Shows Activity in Rare, Aggressive Inflammatory Breast Cancer Subtype

Etira announced the publication of a new open‑access paper showing that its investigational compound ERX‑41 has biological activity against inflammatory breast cancer (IBC), a rare (~2–4%) and extremely aggressive form of the disease with poor survival outcomes. The study found that ERX‑41 can block cancer cell growth and invasion, trigger stress responses in the endoplasmic reticulum, and significantly suppress tumor growth in preclinical xenograft models, with effects dependent on its target protein LIPA. These results build on prior research demonstrating ERX‑41’s mechanism of inducing ER stress and its potential across multiple hard‑to‑treat cancer subsets.